A randomized clinical trial of the effects of supplemental calcium and vitamin D3 on markers of their metabolism in normal mucosa of colorectal adenoma patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

In cancer cell lines and rodent models, calcium and vitamin D favorably modulate cell proliferation, differentiation, and apoptosis in colonic epithelia.

These effects may be modulated by local expression of the calcium receptor (CaR), the vitamin D receptor (VDR), and the P450 cytochromes, CYP27B1 and CYP24A1; however, they have yet to be investigated in humans.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

Topics PubMed links to this paper include 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, Adenoma, Biomarkers, Tumor, Calcium, Cholecalciferol, Colorectal Neoplasms and Immunohistochemistry.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2011 (Cancer research), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.